Categories: Wire Stories

Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021

BEIJING–(BUSINESS WIRE)–Genetron Holdings Limited (�Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar. 26th, 2021.

Sizhen Wang, co-founder and Chief Executive Officer, will also attend a fireside chat at 3:00 pm Beijing time (3:00 am ET).

Interested parties may request more information by contacting their sales representative at Credit Suisse.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Contacts

Investor Relations
US:
Hoki Luk

Head of Investor Relations

Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255

David Deuchler, CFA

Managing Director | Gilmartin Group

Email: David@gilmartinir.com
Phone: (917) 209-5605

Alex

Recent Posts

Zhengzhou: Interactive Exhibitions on the International Museum Day

ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…

8 hours ago

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally

Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…

18 hours ago

Quality Building Award 2024 Unveils Finalist List

QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…

2 days ago

UXLINK Tops RootData’s Latest X Hot Items List and DappRadar Social Apps List

SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…

2 days ago

Australia Construction Industry Report 2024: Growth to Slow to 2% in Real-terms this Year Following 9% Growth in 2023 – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…

2 days ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…

2 days ago